What is BRAIN Biotech AG Operating Cash Flow per Share?
BRAIN Biotech AG's operating cash flow per share for the
three
months ended in Mar. 2024 was €-0.03.
BRAIN Biotech AG's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.09.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 8.90% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 14.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for BRAIN Biotech AG's Operating Cash Flow per Share or its related term are showing as below:
XTER:BNN'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: 2.1 Med: 11.55 Max: 31.2
Current: 8.9
During the past 9 years, BRAIN Biotech AG's highest 3-Year average Operating Cash Flow per Share Growth Rate was 31.20% per year. The lowest was 2.10% per year. And the median was 11.55% per year.
XTER:BNN's 3-Year OCF Growth Rate is ranked better than 58.97% of 1248
companies
in the Chemicals industry
Industry Median: 3
vs XTER:BNN: 8.90
BRAIN Biotech AG Operating Cash Flow per Share Historical Data
The historical data trend for BRAIN Biotech AG's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
BRAIN Biotech AG Operating Cash Flow per Share Chart
Competitive Comparison of BRAIN Biotech AG's Operating Cash Flow per Share
For the Specialty Chemicals subindustry, BRAIN Biotech AG's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG's Price-to-Operating-Cash-Flow Distribution in the Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's Price-to-Operating-Cash-Flow falls into.
BRAIN Biotech AG Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
BRAIN Biotech AG's Operating Cash Flow per Share for the fiscal year that ended in Sep. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.09
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRAIN Biotech AG Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of BRAIN Biotech AG's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XTER:BNN has been successfully added to your 